Related Experiment Video
Updated: Oct 11, 2025
Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study
Ida Manna1, Andrea Quattrone2, Selene De Benedittis2
1Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Section of Germaneto, 88100, Catanzaro, Italy.
Introduction:
Parkinson's disease (PD), a progressive neurodegenerative disease, can be misdiagnosed with atypical conditions such as Progressive Supranuclear Paralysis (PSP) due to overlapping clinical features. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in post-transcriptional gene regulation. The aim was to identify a set of differential exosomal miRNAs biomarkers, which may aid in diagnosis.
Methods:
We analyzed the serum level of 188 miRNAs in a discovery set, by using RTqPCR based TaqMan assay, in a small cohort of healthy controls, PD and PSP patients. Subsequently, the differentially expressed miRNAs, between PSP and PD patients, were further tested in a larger and independent cohort of 33 healthy controls, 40 PD and 20 PSP patients. The most accurate diagnostic exosomal miRNAs classifiers were identified in a logistic regression model.
Results:
A statistically significant set of three exosomal miRNAs: miR-21-3p, miR-22-3p and miR-223-5p, discriminated PD from HC (area under the curve of 0.75), and a set of three exosomal miRNAs, miR-425-5p, miR-21-3p, and miR-199a-5p, discriminated PSP from PD with good diagnostic accuracy (area under the curve of 0.86). Finally, the classifier that best discriminated PSP from PD consisted of six exosomal miRNAs (area under the curve = 0.91), with diagnostic sensitivity and specificity of 0.89 and 0.90, respectively.
Conclusions:
Based on our analysis, these data showed that exosomal miRNAs could act as biomarkers to differentiate between PSP and PD.
Insights
Exosomal microRNAs show promise as biomarkers for distinguishing Parkinson's disease (PD) from Progressive Supranuclear Paralysis (PSP). A panel of six exosomal microRNAs achieved high accuracy in differentiating these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Molecular Biology
Background:
- Parkinson's disease (PD) and Progressive Supranuclear Paralysis (PSP) are often misdiagnosed due to similar clinical symptoms.
- Accurate differential diagnosis is crucial for appropriate patient management and treatment.
- MicroRNAs (miRNAs), particularly exosomal miRNAs, are emerging as potential diagnostic biomarkers.
Purpose of the Study:
- To identify a panel of exosomal microRNAs that can accurately differentiate between PD and PSP.
- To evaluate the diagnostic potential of these microRNAs in serum samples.
Main Methods:
- Serum samples from healthy controls, PD patients, and PSP patients were analyzed for 188 miRNAs using RTqPCR.
- Differential expression analysis was performed to identify candidate miRNAs.
- Logistic regression models were used to develop diagnostic classifiers.
Main Results:
- A set of three exosomal miRNAs distinguished PD from healthy controls (AUC=0.75).
- A distinct set of three exosomal miRNAs differentiated PSP from PD with good accuracy (AUC=0.86).
- A classifier of six exosomal miRNAs achieved high diagnostic accuracy (AUC=0.91) for discriminating PSP from PD, with 89% sensitivity and 90% specificity.
Conclusions:
- Exosomal miRNAs can serve as reliable biomarkers for differentiating between PD and PSP.
- The identified miRNA panels offer potential for improved diagnostic tools for these neurodegenerative diseases.
More Related Videos
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
08:49Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
